Researchers, health professionals, consumer groups and advocates in the field have repeatedly called for widespread availability of naloxone for people who inject drugs and potential overdose witnesses, to reduce the incidence of fatal overdose.
Treatment and Intervention
Heroin use and associated harms can be reduced through effective treatment. Past research has shown that treatment for heroin dependence can be relatively cost-effective, but not whether heroin treatment overall is a good investment.
Drug dependence is a chronic relapsing condition, associated with high levels of psychopathology.
Limited research suggests a strong association between adult Attention Deficit Hyperactivity Disorder (ADHD) and substance use disorders (SUD), with adult ADHD over-represented among people with substance use problems (20-40% prevalence).
There has been a recent increase in the prescribing of pharmaceutical opioids to Chronic Non-Cancer Pain (CNCP) patients in Australia which has led to increasing professional and public concern about the use and harms that may be related to such use.
NIDIP was established in the recognition that there was a greater need for the regular dissemination of trends in the epidemiology of drug-related harms in Australia.
There are growing efforts by pharmaceutical companies to develop opioid formulations that are less prone to misuse (particularly injection), dependence and diversion to illicit markets.
This project examines the cost-effectiveness of an integrated community development approach for reducing alcohol-related injury and violence among Aboriginal people in three rural locations in NSW.
There has been limited examination of how prisoners view and experience opioid substitution treatment (OST). This project aims to describe OST within NSW correctional centres and patient experiences of being in OST while in prison.